tbuckley/cabot-search huggingface dataset:
Abstract 6072: Waitlist Mortality for Infants Awaiting Heart Transplantation in the United States in the Current Era: Analysis of Data from the United Network for Organ Sharing
Authors: Doug Mah, Tajinder Singh, Ravi R Thiagarajan, Kimberlee Gauvreau, Gary E Piercey, Francis Fynn-Thompson, Christopher S Almond
Journal: Circulation (2008)

BACKGROUND UNOS (United Network for Organ Sharing) data suggest that of all pediatric transplant candidates, infants awaiting heart transplantation face the highest waitlist mortality. We sought to determine the mortality rate for waitlisted infants in the current era and to identify the risk factors associated with waitlist mortality. METHODS In this multi-center cohort study using the US Scientific Registry of Transplant Recipients, we analyzed all infants &lt;12 months of age listed for first heart transplant between January 1999 and July 2006. Clinical and demographic characteristics were recorded at the time of listing. Multivariate logistic regression modeling was used to identify predictors of waitlist mortality. RESULTS In this six year period, 1133 patients less than 12 months of age were identified with a median age of 1 month (IQR 0 to 5 mo) and median weight of 4.0 kg (IQR 3.2 to 5.6 kg). 516 (45%) were female, 438 (39%) were non-white, 724 (64%) had congenital heart disease (CHD) and 910 (80%) were listed status 1A. Overall, 250 (22%) died while waiting including 179 (72%) listed at age &lt;3 mo, 190 (76%) with CHD, 89 (35%) listed on mechanical ventilation, and 68 (27%) on ECMO. In multivariate analysis, risk factors for waitlist mortality (reported as hazard ratio, 95% CI) included age &lt;3 months (1.5, 1.1–2.0), CHD (2.0, 1.5–2.7), ventilator support (2.0, 1.5–2.7), ECMO support (5.0, 3.6 –7.0) and non-white race (1.7, 1.4 –2.2). CONCLUSION Mortality of infants waiting for heart transplantation remains high with a 22% waitlist mortality in the current era. ECMO support, ventilator support, CHD, age less than 3 months, and non-white race were independently associated with waitlist mortality whereas listing status was not. Measures to improve donor availability for this age group and refinements in organ allocation to lower waitlist mortality are urgently needed.
Identification Of The Disease-Causing Mutation In Autosomal Dominant Familial Immune Thrombocytopenia By Genome-Wide Linkage Analysis and Whole Genome Sequencing
Authors: Bing Zhang, Yoonha Choi, Dana Ng, Ziming Weng, Clara Lo, Yohannes Ghebremariam, Engin Özkan, Chun-Ping Liao, Susumu Inoue, Joachim Hallmayer, Christopher Garcia, John Cooke, Hua Tang, Arend Sidow, James L. Zehnder
Journal: Blood (2013)
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Authors: Daming Shan, Jeffrey A. Ledbetter, Oliver W. Press
Journal: Blood (1998)

Abstract CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this B-cell surface antigen has been shown recently to be an effective target for immunotherapy of B-cell malignancies using chimeric (mouse/human) or radiolabeled murine monoclonal anti-CD20 antibodies. In this report we show that extensive crosslinking of CD20 with murine anti-CD20 monoclonal antibodies (MoAbs) in the presence of either goat anti-mouse IgG or Fc receptor (FcR)-expressing cells directly inhibits B-cell proliferation, induces nuclear DNA fragmentation, and leads to cell death by apoptosis. The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20–mediated apoptosis may be related to changes in Ca2+ concentration. These findings suggest that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti-CD20 MoAbs.
Abstract 14863: Genetically Engineered Mesenchymal Stem Cells Confer Beneficial Effects on Both Co-transplanted Human Embryonic Stem Cell Derived Cardiomyocytes as well as the Recipient Heart
Authors: Mary Kearns-Jonker, Wangde Dai, Mirja Gunthart, Nandini Girish, Martin Pera, Christine Mummery, Robert A Kloner
Journal: Circulation (2010)

Introduction:  Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) or mesenchymal stem cells (MSCs) facilitate post-infarct recovery. MSCs produce paracrine factors that promote cardiac repair, but are insufficient for cardiac regeneration.   Hypothesis:  Optimal cell therapy may require co-transplantation of MSCs together with hESC-CMs to facilitate angiogenesis and stem cell survival.   Methods:  MSCs were engineered to over-express the cytoprotective gene hemeoxygenase-1 (HO-1) to promote cardiovascular repair. Gene expression changes in hESC-CMs  in vivo  were identified to reveal the mechanisms underlying apoptosis and survival. Four experimental groups of athymic nude rats were subjected to myocardial infarction (n=15 per group) and received hESC-CMs alone, hESC-CMs plus human MSCs, hESC-CMs plus MSCs overexpressing HO-1, or saline by intramyocardial injection. Real time PCR and laser capture microdissection identified gene expression changes. Cardiac function was assessed by angiography at 4 weeks.   Results:  Sizable grafts of human cells were identifiable by histology at 30 days. Co-transplantation of unmodified MSCs plus hESC-CMs resulted in highly elevated Bcl2 and CCL5 levels in human cardiomyocytes relative to pre-transplant levels and a 25–30 fold increase in human collagen and fibronectin. In animals co-transplanted with MSC over-expressing HO-1, relative quantities of human VEGF, TGF-β, and CSF-1 transcripts were increased 5 fold and Bcl2 was increased logarithmically. STAT 3 and AKT transcripts were elevated. Human Isl-1 gene expression rose 1.7 fold. Laser capture microdissection revealed a 1.4 fold increase in human CD31 transcripts. Rat troponin T and rat CD31 gene expression increased by 1.9–2.7 fold and 1.2–1.5 fold respectively. Stem cell treatment improved ejection fraction by an absolute increase of 6.3 to 6.7 +/− 1.5 percentage points above controls.   Conclusions:  Co-administration of HO-1 MSCs plus hESC-CMs increased the expression of pro-survival and angiogenesis-promoting genes in the transplanted human cells and increased endogenous cardiac and endothelial cell markers in rodent cells, consistent with activation of tissue repair in both the transplanted hESC-CMs as well as the host heart.
Pregnancy and delivery require a joint midwifery and medical approach
Authors: C. Lees, S. Campbell, L. Cardozo, D. Gibb, M. Blott, I. White
Journal: BMJ (1995)

EDITOR,—We believe that V A Hundley and colleagues make observations about midwife managed versus consultant led care that are potentially midleading.1 The assertion that there is no increase in adverse neonatal outcomes associated with midwife managed care is not justified by the neonatal mortality quoted; our calculation of the relative risk of neonatal death in the midwives …
Abstract 3078: Myocardial Collagen Metabolism In Failing Hearts Before And During Cardiac Resynchronization Therapy
Authors: Soban Umar, Jeroen J Bax, Margreet Klok, Marleen H Hessel, Brigit den Adel, Gabe B Bleeker, Maureen M Henneman, Douwe E Atsma, EE van der Wall, MJ Schalij, Arnoud van der Laarse
Journal: Circulation (2007)

Objective Cardiac resynchronization therapy (CRT) has proven efficacy in improving left ventricular ejection fraction (LVEF), LV diastolic function, NYHA functional class and outcome in patients with congestive heart failure (CHF), although a substantial number of patients respond poorly to CRT. We investigated whether myocardial collagen metabolism of patients with CHF is implicated in good or poor response to CRT. Methods We analyzed collagen synthesis and degradation by measuring the concentrations of aminoterminal propeptides of type I and type III collagen (PINP and PIIINP, resp.) and carboxyterminal telopeptide of type I collagen (ICTP), respectively, in serum of 64 patients with CHF before and 6 months after start of CRT. Patients had NYHA class III–IV, LVEF ≤35%, and QRS duration &gt;120 ms. Results In 46 patients, CRT resulted in &gt;10% reduction of LV end-systolic volume (LVESV), referred to as responders, whereas in 18 patients LVESV did not change upon CRT or even increased, referred to as non-responders. Responders demonstrated an increase of serum PINP and PIIINP upon CRT, from 32.9±2.2 to 46.7±4.0 μg/L (p&lt;0.001) and from 4.59±0.24 to 5.13±0.36 μg/L (p&lt;0.05), respectively, whereas serum PINP and PIIINP of non-responders did not change upon CRT (from 41.8±4.3 to 43.8±6.2 μg/L and from 4.03±0.45 to 4.28±0.31 μg/L, resp.). Responders had higher serum levels of ICTP at baseline and at 6 months follow-up (from 3.38±0.54 to 3.12±0.48 μg/L) than non-responders at both time points (from 1.96±0.37 to 1.92±0.38 μg/L), although these differences were not statistically significant. Conclusion Compared to future non-responders to CRT, future responders demonstrate relatively low levels of markers of collagen synthesis and relatively high levels of markers of collagen degradation at baseline. Unlike non-responders, responders show an increase in collagen synthesis in the first 6 months of CRT.
Decrease in CD4+CD25-/CD4+CD25+ Treg ratio in thoracic lymph nodes in early stage of lung carcinogenesis: reversal by α-Tocopheryl succinate in vitro and implications for lung cancer Immunotherapy
Authors: Mehdi Fini, Nathan Pennock
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

223 

There are many reports indicating the role of local and systemic immunodeficiency in the promotion and progression of different human cancers. These include the diminishing function of tumor-specific T cells concurrent with tumor progression and infiltration of suppressor T-cell during the early stage of tumorigenesis in the tumor microenvironment. α-Tocopheryl succinate (α-TS) is a semisynthetic ester analog of vitamin E derived by substituting the hydroxyl group of vitamin E (α-tocopherol) with a succinyl group. Tocopheryl succinate and not vitamin E has been shown to kill lung cancer cells and many other kinds of cancer cells, but not normal cells. α-TS has also immunomodulatory properties and has shown promising results as novel adjuvant to augment the effectiveness of DC-based vaccines. In this study we used the A/J mouse model of lung cancer to study the different ratio of T cell subsets in different regional lymph nodes and assess their ratio in relation to tumor progression. We further studied the effect of α-TS on peripheral T cell proliferation and assessed its toxicity on different T cell subsets in vitro . Our in vivo results showed the diminished ratio of CD4+CD25-/CD4+CD25+ (Treg) in thoracic lymph nodes as compared to purified cells from spleen and peripheral lymph nodes of tumor burdened mice ( p<0.01 ). This was also associated with diminished CD4+/CD8+ ratio in a similar pattern (p<0.0002). Our in vitro experiments showed that α-TS even at 40 μM (IC50 dose) had no toxic, apoptotic or adverse effects on the proliferation or the activation of T cells. Interestingly we found that dose response effect of α-TS treatment in vitro was associated with reversal of CD4+CD25-/CD4+CD25+ (Treg) ratio and CD4+/CD8+ ratio (p<0.01). Further ongoing studies will fully characterize the role of this compound in combination chemotherapy with other chemotherapeutic drugs in vitro and in vivo which will help to design novel immunotherapeutic strategies for the prevention of T-cell immunosuppression in cancer patients. [Supported in part by grants from: American Cancer Society: ACS-PF-06-005-01-CCE, NIH-NCI-CA112652, Cancer Research and Prevention Foundation]
Abstract 2059: Differences between Site-Reported and Core Laboratory Creatine Kinase-MB Values in an International Clinical Trial: Results from the SYNERGY Trial
Authors: Jason P Linefsky, Kenneth W Mahaffey, Karen S Pieper, Annie Lin, Craig J Reist, Elliott Antman, Shaun G Goodman, John K French, Matthew T Roe, Robert A Harrington, James J Ferguson, Robert M Califf
Journal: Circulation (2006)
Impact of a Worksite Intervention Program on Cardiovascular Risk Factors
Authors: Dorairaj Prabhakaran, Panniyammakal Jeemon, Shifalika Goenka, Ramakrishnan Lakshmy, K.R. Thankappan, Faruq Ahmed, Prashant P. Joshi, B.V. Murali Mohan, Ramanathan Meera, Mohas S. Das, Ramesh C. Ahuja, Ram Kirti Saran, Vivek Chaturvedi, K. Srinath Reddy
Journal: Journal of the American College of Cardiology (2009)
Abstract 15151: Impact of Multivessel Revascularization on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating ST-Segment Elevation Acute Myocardial Infarction and Multivessel Disease
Authors: Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Hyeon-Cheol Gwon
Journal: Circulation (2011)

Background:  In acute ST elevation myocardial infarction (STEMI) without cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI), the current guidelines do not recommend intervention on nonculprit vessels. However, no data are available in CS patients with STEMI and multivessel disease. We investigated whether multivessel revascularization is associated with improved survival in hospital.   Methods:  A total of 509 patients with CS complicating STEMI treated with primary PCI, 240 patients with multivessel disease were selected from a nationwide, prospective Korea Working Group on Myocardial Infarction (KorMI) registry from January 2008 to September 2010. Primary end point was in-hospital death.   Results:  In-hospital mortality was 27.1% for CS. Non-culprit coronary interventions were performed at the time of primary PCI in 51 (21.3%) patients. Independent predictors of in-hospital mortality included age ≥ 75 years ( P  = 0.046, odd ratio (OR) = 2.37, 95% confidence interval (CI): 1.02-5.52), sinus rhythm on admission ( P  = 0.008, OR = 0.35, 95% CI: 0.16-0.76), left ventricular ejection fraction  P  = 0.001, OR = 3.98, 95% CI: 1.80-8.78), and glucose serum level > 200mg/dl ( P  = 0.041, OR = 2.18, 95% CI: 1.03-4.62). However, multivessel revascularization is not independent predictor of in-hospital mortality ( P  = 0.383, OR=1.46, 95% CI: 0.62-3.43)   Conclusions:  Multivessel revascularization was not associated with improved survival in CS patients with STEMI and multivessel disease undergoing primary PCI.
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection
Authors: Lynn Gerber, Michael Estep, Maria Stepanova, Carey Escheik, Ali Weinstein, Zobair M Younossi
Journal: Clinical Gastroenterology and Hepatology (2015)
APP intracellular domain–WAVE1 pathway reduces amyloid-β production
Authors: Ilaria Ceglia, Christiane Reitz, Jodi Gresack, Jung-Hyuck Ahn, Victor Bustos, Marina Bleck, Xiaozhu Zhang, Grant Martin, Sanford M Simon, Angus C Nairn, Paul Greengard, Yong Kim
Journal: Nature Medicine (2015)
Abstract 14672: Blue Light During Pericardioscopy Improves the Diagnostic Yield of Epicardial and Pericardial Biopsy
Authors: Bernhard Maisch, Roland Moll, Ulrik Baandrup, Sabine Pankuweit
Journal: Circulation (2011)

Background: Epi- and pericardial biopsy guided by pericardioscopy has improved the diagnostic yield in patients(pts) with “idiopathic” pericarditis undergoing pericardiocentesis. Additional etiopat...
Abstract 9790: Central Venous Pressure After Coronary Artery Bypass Surgery: Does it Predict Postoperative Mortality or Renal Failure?
Authors: Judson B Williams, Eric D Peterson, Daniel Wojdyla, Kevin W Southerland, T. Bruce Ferguson, Peter K Smith, Carmelo A Milano, Renato D Lopes
Journal: Circulation (2013)

Background: While hemodynamic monitoring is often performed following coronary artery bypass grafting (CABG), the role of monitoring postoperative central venous pressure (CVP) measurement as a predictor of clinical outcomes is unknown. Methods: Detailed clinical data were analyzed from 2,390 randomly selected patients undergoing high risk CABG or CABG/valve at 55 hospitals participating in the Society of Thoracic Surgeons’ National Cardiac Surgery Database from 2004 to 2005. Eligible patients underwent elective/urgent isolated CABG with an ejection fraction &lt; 40%, or elective/urgent CABG at age ≥65 years with diabetes or a glomerular filtration rate 60 mL/min per 1.73 m 2 . Correlation between post-operative CVP and in-hospital / 30-day mortality and renal failure was assessed as a continuous variable, both unadjusted and after adjusting for important clinical factors using logistic regression modeling. Results: Mean age was 72 years, 54% of patients had diabetes mellitus, 49% were urgent procedures, and mean cardiopulmonary bypass time was 105 minutes. Patients’ CVP 6 hours post-operation was strongly associated with in-hospital and 30 day mortality: odds ratio (OR) 1.5 (95% confidence interval [CI] 1.23, 1.87) for every 5 mmHg increase in CVP, p&lt;0.0001. This association remained significant after risk-adjustment for cardiac index: adjusted OR 1.44 (95% CI 1.10, 1.89), p&lt;0.01. A model adjusting for cardiac index also revealed increased incidence of mortality or renal failure: adjusted OR 1.5 (95% CI 1.28, 1.86) for every 5 mmHg increase in CVP, p&lt;0.0001. Conclusion: Patients’ central venous pressure at 6 hours following CABG surgery was highly predictive of operative mortality or renal failure, independent of cardiac index and other important clinical variables. Future studies will need to assess whether interventions guided by post-operative CVP can improve patient outcomes.
A Potential Solution for Research Misconduct
Authors: Kim Pepitone, Sandeep Kamat
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Defining the mechanisms by which leptin stimulates proliferation of ovarian cancer cells
Authors: A. B. Olawaiye, H. Sakamoto, T. Serikawa, A. Friel, R. Kiyama, A. Inoue, R. Drapkin, R. Foster, R. R. Gonzalez, B. R. Rueda
Journal: Journal of Clinical Oncology (2006)

15017 Background: Ovarian cancer (OvCa) ranks fourth as the cause of death related to cancer in women in the U.S. The vast majority (&gt;90%) of OvCa originates from the ovarian surface epithelium. There is sufficient evidence to suggest that hormones, especially estrogen, may be involved in the etiopathogenesis of epithelial OvCa. Recent studies indicate that leptin participates either directly or indirectly to promote carcinogenesis in both breast and endometrial cancers. Furthermore it has been proposed that leptin may elicit its action via an estrogen related pathway. Leptin can stimulate proliferation of some OvCa cell lines and has been implicated as a potential biomarker for OvCa. However the mechanism(s) by which leptin contributes to the growth of OvCa has yet to be defined. We hypothesize that leptin’s effect will be mediated in part by estrogen receptor (ER) pathways. Methods: Three epithelial OvCa cell lines (IGROV1, OVCAR5 and TOV21G) and one benign human ovarian surface epithelial cell line (HOSE) were evaluated. Enzyme linked immunosorbent assay (ELISA) and Western blotting were used to assess leptin and leptin receptor (ObR), respectively. Leptin (0.06 nM–6.25 nM) induced effects on cell proliferation were assessed in the presence or absence of an aromatase enzyme inhibitor (Anastrozole) or the ER antagonist (ICI182780). Further, we explored leptin-induced effects on ERα promoter activity as evidenced by change in fluorescence via a dual luciferase promoter reporter. All experiments were conducted in triplicate. All data were subjected to ANOVA followed by Tukey’s post hoc test (p &lt; 0.05). Results: All ovarian cell lines expressed ObR; whereas, no measurable amounts of leptin were detected in conditioned media. Leptin stimulated cell proliferation in both the benign and malignant lines. Leptin-induced cell proliferation was inhibited by Anastrozole and ICI182780. Furthermore, leptin stimulated luciferase activity of the ERα promoter/reporter. Conclusions: Leptin promotes proliferation of benign and malignant ovarian epithelial cells and appears to be mediated, at least in part, via aromatase and ER which may have therapeutic implications. This work was supported by the Vincent Memorial Hospital, SG Komen Foundation and the Advanced Medical Research Foundation. No significant financial relationships to disclose.
Numbers and Percentages Of Peripheral Monocytes Is a Prognostic Marker For CNS Involvement In Diffuse Large B-Cell Lymphoma
Authors: Hideaki Nitta, Yasuhito Terui, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Aya Ouchi, Naoko Tsuyama, Kengo Takeuchi, Kiyohiko Hatake
Journal: Blood (2013)